You have a stack of serum samples, a semaglutide study to report, and a choice that will shape the next few weeks: ELISA or LC-MS/MS?
Both can work. Which one works better depends on three things: how many samples you have, how low the concentrations go, and whether other GLP-1 drugs could be in the mix. Here is how we think about it after years of making and supporting GLP-1 ELISA kits.
In short
- Choose ELISA for volume, speed and routine work: formulation, release, stability, biosimilar comparisons and study samples you have validated yourself.
- Choose LC-MS/MS for the lowest concentrations, or when more than one GLP-1 agonist could be present.
- For decisions that matter, use both: ELISA for the bulk, LC-MS/MS as the check.
Why is semaglutide tricky to measure?
Semaglutide is a modified GLP-1 peptide designed to stay in the body for about a week. That design creates three problems for the analyst.
- It binds albumin tightly. Recovery depends on how you handle the sample.
- It sticks to plastic. Labware and diluents change low-level results.
- It resembles other GLP-1 drugs. Specificity needs thought.
What concentrations should you expect?
Published data put steady-state Cmax at about 100 ng/mL for a 0.5 mg weekly dose and about 200 ng/mL for 1.0 mg (Irie et al., 2018). Troughs, early timepoints and lower doses sit below that. Work out your own range first, because it decides everything that follows.
When does ELISA make sense?
Most of the time, if you have many samples and a known drug.
A competitive ELISA needs only a plate reader. Our KRIBIOLISA Semaglutide ELISA (KBI5030) runs in about 4.5 hours, handles a full plate in one go, and gives reproducible numbers: intra-assay precision below 10% at the low end and below 8% across the mid and high range. The kit was validated in line with EMA and FDA bioanalytical guidance, and natural GLP-1 does not interfere (below 0.1% cross-reactivity).
The standard curve runs from 50 to 4,000 ng/mL, with samples diluted 1:100. That suits formulations, release testing, stability studies and high-exposure samples. For lower-concentration serum, labs validate a lower dilution in their own matrix, as ICH M10 expects of any ligand-binding assay.
One thing to know
The antibody recognises the GLP-1 agonist class. Liraglutide and tirzepatide read at 100–120%, like semaglutide. If you know which drug was dosed, that is no problem. If you don’t, confirm by LC-MS/MS.
When is LC-MS/MS the better choice?
When you need to go very low, or you need to prove which molecule you are looking at.
LC-MS/MS identifies semaglutide by mass, so it tells analogues apart and reaches sub-ng/mL levels. A published Waters method reports an LLOQ of 0.1 ng/mL with CV below 8% (Waters, 2023). The price is time and equipment: a mass spectrometer, an experienced operator, longer sample prep, and a queue.
Side by side
Five habits that improve results with either method
Validate in your own matrix
Not just kit buffer.
Run spike recovery
To check for matrix effects.
Check dilution linearity
So samples behave like the standards.
Use low-binding labware
And handle every sample the same way.
Follow ICH M10
From the start, if results go into a submission.
Quick answers
Can I use an ELISA on serum?
Yes. KBI5030 accepts serum and plasma.
Does it work in rat or mouse?
The kit is validated for human samples. We offer custom rat and mouse validation for a small additional fee.
For research use only.
Need help choosing?
Tell us your matrix, dose and expected range, and our application team will suggest a starting dilution and plan.
References
- Irie S, et al. Adv Ther. 2018;35(4):531–544. PMC5910468
- Waters Corporation. Quantification of semaglutide in human plasma (2023).
- Krishgen Biosystems. KBI5030 datasheet, Ver 6.7.
- ICH M10: Bioanalytical Method Validation and Study Sample Analysis.
